Electronic Cigarettes for Smoking Cessation

Current Cardiology Reports

Volumn 16, Issue 11, 2014, Pages 1-8

  Bullen, Christopher ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Cessation; Dependence; E cigarettes; Electronic cigarettes; Harm reduction; Nicotine; Smoking; Tobacco

Indexed keywords

ELECTRONIC CIGARETTE; NICOTINE PATCH; NICOTINIC RECEPTOR; NICOTINE; NICOTINE GUM;

AEROSOL; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; EVIDENCE BASED PRACTICE; HEALTH CARE POLICY; HEALTH HAZARD; HUMAN; MOTIVATION; NICOTINE REPLACEMENT THERAPY; PARTICULATE MATTER; PROGRAM EFFECTIVENESS; PROTEIN BINDING; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SALIVA LEVEL; SMOKING; SMOKING CESSATION; SMOKING CESSATION PROGRAM; ATTITUDE TO HEALTH; OUTCOME ASSESSMENT; PREVENTION AND CONTROL; PROCEDURES; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUBSTANCE WITHDRAWAL SYNDROME; TIME;

ELECTRONIC CIGARETTES; EVIDENCE-BASED PRACTICE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; NICOTINE; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMOKING; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS; TOBACCO USE CESSATION PRODUCTS;

EID: 84910660637     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-014-0538-8     Document Type: Review

References (67)

1. Warner KE. Cost effectiveness of smoking-cessation therapies. Interpretation of the evidence-and implications for coverage. Pharm Econ. 1997;11:538–49.
2. Fagerstrom K, Hughes J. Varenicline in the treatment of tobacco dependence. Neuropsychiatr Dis Treat. 2008;4:353–63.
3. Stead L, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2011;11:CD000146.
4. Fiore MC, Schroeder SA, Baker TB. Smoke, the chief killer—strategies for targeting combustible tobacco use. N Engl J Med. 2014;370:297–9.
5. Adkison SE, O’Connor RJ, Bansal-Travers M, Hyland A, Borland R, Yong H-H, et al. Electronic nicotine delivery systems: international tobacco control four-country survey. Am J Prev Med. 2013;44:207–15.
6. Abrams DB. Promise and peril of e-cigarettes: can disruptive technology make cigarettes obsolete? JAMA. 2014;311:135–6. This article provides an excellent overview of the potential benefits and harms of e-cigarettes at individual and population levels and has provoked a debate suggesting that e-cigarettes may have a role in tobacco control.
7. McQueen A, Tower S, Sumner W. Interviews with “vapers”: implications for future research with electronic cigarettes. Nicotine Tob Res. 2011;13:860–7.
8. Noel JK, Rees VW, Connolly GN. Electronic cigarettes: a new ‘tobacco’ industry? Tob Control. 2011;20:81.
9. Grana RA, Ling PM. “Smoking revolution”: a content analysis of electronic cigarette retail websites. Am J Prev Med. 2014;46:395–403.
10. Regan AK, Promoff G, Dube SR, Arrazola R. Electronic nicotine delivery systems: adult use and awareness of the ‘e-cigarette’ in the USA. Tob Control. 2013;22:19–23.
11. Tan ASL, Bigman CA. E-cigarette awareness and perceived harmfulness: prevalence and associations with smoking-cessation outcomes. Am J Prev Med. 2014;47:141–9. doi:10.1016/j.amepre.2014.02.011.
12. King BA, Alam S, Promoff G, Arrazola R, Dube SR. Awareness and ever use of electronic cigarettes among U.S. Adults, 2010–2011. Nicotine Tob Res. 2013;15:1623–7. doi:10.1093/ntr/ntt013.
13. Zhu SH, Gamst A, Lee M, Cummins S, Yin L, Zoref L. The use and perception of electronic cigarettes and snus among the U.S. population. PLoS One. 2013;8:e79332. doi:10.1371/journal.pone.0079332. The article provides recent survey data on e-cigarette use drawing on a robust sample of the US population.
14. Grana RA. Electronic cigarettes: a new nicotine gateway? J Adolesc Health. 2013;52:135–6.
15. Corey C, Wang B, Johnson SE, Apelberg B, Husten C, King BA, et al. Cancer-related news from the CDC: electronic cigarette use among middle and high school students. Oncol Times. 2013;35:36.
16. Zhu S-H, Sun JY, Bonnevie E, Cummins SE, Gamst A, Yin L, et al. Four hundred and sixty brands of e-cigarettes and counting: implications for product regulation. Tob Control. 2014;23:iii3–9.
17. Brown CJ, Cheng JM. Electronic cigarettes: product characterisation and design considerations. Tob Control. 2014;23:ii4–10.
18. Etter J-F. Electronic cigarettes: a survey of users. BMC Public Health. 2010;10:231.
19. Vickerman KA, Carpenter KM, Altman T, Nash CM, Zbikowski SM. Use of electronic cigarettes among state tobacco cessation quitline callers. Nicotine Tob Res. 2013;15:1787–91. doi:10.1093/ntr/ntt061.
20. Pepper JK, Brewer NT. Electronic nicotine delivery system (electronic cigarette) awareness, use, reactions and beliefs: a systematic review. Tob Control. 2013. doi:10.1136/tobaccocontrol-2013-051122.
21. Benowitz NL. Nicotine addiction. N Engl J Med. 2010;362:2295–303.
22. Wullner U, Gundisch D, Herzog H, Minnerop M, Joe A, Warnecke M, et al. Smoking upregulates alpha4beta2* nicotinic acetylcholine receptors in the human brain. Neurosci Lett. 2008;430:34–7.
23. Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD000146.
24. Bullen C, McRobbie H, Thornley S, Glover M, Lin R, Laugesen M. Effect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preferences and nicotine delivery: randomised cross-over trial. Tob Control. 2010;19:98–103.
25. Eissenberg T. Electronic nicotine delivery devices: ineffective nicotine delivery and craving suppression after acute administration. Tob Control. 2010;19:87–8.
26. Vansickel AR, Eissenberg T. Electronic cigarettes: effective nicotine delivery after acute administration. Nicotine Tob Res. 2013;15:267–70.
27. Goniewicz ML, Kuma T, Gawron M, Knysak J, Kosmider L. Nicotine levels in electronic cigarettes. Nicotine Tob Res. 2013;15:158–66.
28. Zhang Y, Sumner W, Chen D-R. In vitro particle size distributions in electronic and conventional cigarette aerosols suggest comparable deposition patterns. Nicotine Tob Res. 2013;15:501–8.
29. Etter JF, Bullen C. Saliva cotinine levels in users of electronic cigarettes. Eur Respir J. 2011;38:1219–20.
30. Williams M, Talbot P. Variability among electronic cigarettes in the pressure drop, airflow rate, and aerosol production. Nicotine Tob Res. 2011;13:1276–83.
31. Schroeder MJ, Hoffman AC. Electronic cigarettes and nicotine clinical pharmacology. Tob Control. 2014;23:ii30–5.
32. Hua M, Yip H, Talbot P. Mining data on usage of electronic nicotine delivery systems (ENDS) from YouTube videos. Tob Control. 2013;22:103–6.
33. Farsalinos KE, Spyrou A, Tsimopoulou K, Stefopoulos C, Romagna G, Voudris V. Nicotine absorption from electronic cigarette use: comparison between first and new-generation devices. Sci Rep. 2014;4:4133.
34. Vansickel AR, Weaver MF, Eissenberg T. Clinical laboratory assessment of the abuse liability of an electronic cigarette. Addiction. 2012;107:1493–500.
35. Dawkins L, Turner J, Hasna S, Soar K. The electronic-cigarette: effects on desire to smoke, withdrawal symptoms and cognition. Addict Behav. 2012;37:970–3.
36. Dale LC, Hurt RD, Offord KP, Lawson GM, Croghan IT, Schroeder DR. High-dose nicotine patch therapy. Percentage of replacement and smoking cessation. JAMA. 1995;274:1353–8.
37. Buchhalter AR, Acosta MC, Evans SE, Breland AB, Eissenberg T. Tobacco abstinence symptom suppression: the role played by the smoking-related stimuli that are delivered by denicotinized cigarettes. Addiction. 2005;100:550–9.
38. Brody AL, Mandelkern MA, Costello MR, Abrams AL, Scheibal D, Farahi J, et al. Brain nicotinic acetylcholine receptor occupancy: effect of smoking a denicotinized cigarette. Int J Neuropsychopharmacol. 2009;12:305–16.
39. Hajek P, McRobbie H, Gillison F. Dependence potential of nicotine replacement treatments: effects of product type, patient characteristics, and cost to user. Prev Med. 2007;44:230–4. doi:10.1016/j.ypmed.2006.10.005.
40. Berlin I, Anthenelli RM. Monoamine oxidases and tobacco smoking. Int J Neuropsychopharmacol. 2001;4:33–42.
41. Carpenter CM, Wayne GF, Connolly GN. The role of sensory perception in the development and targeting of tobacco products. Addiction. 2007;102:136–47.
42. Wagener TL, Meier E, Hale JJ, Oliver ER, Warner ML, Driskill LM, et al. Pilot investigation of changes in readiness and confidence to quit smoking after e-cigarette experimentation and 1 week of use. Nicotine Tob Res. 2014;16:108–14.
43. Etter JF, Bullen C. Electronic cigarette: users profile, utilization, satisfaction and perceived efficacy. Addiction. 2011;106:2017–28.
44. Grana RA, Popova L, Ling PM. A longitudinal analysis of electronic cigarette use and smoking cessation. JAMA Int Med. 2014;174:813–4.
45. Caponnetto P, Cibella F, Mancuso S, Campagna D, Arcidiacono G, Polosa R. Effect of a nicotine-free inhalator as part of a smoking-cessation programme. Eur Respir J. 2011;38:1005–11.
46. Caponnetto P, Polosa R, Russo C, Leotta C, Campagna D. Successful smoking cessation with electronic cigarettes in smokers with a documented history of recurring relapses: a case series. J Med Case Rep. 2011;5:585.
47. Polosa R, Caponnetto P, Morjaria JB, Papale G, Campagna D, Russo C. Effect of an electronic nicotine delivery device (e-cigarette) on smoking reduction and cessation: a prospective 6-month pilot study. BMC Public Health. 2011;11:786.
48. Caponnetto P, Campagna D, Cibella F, Morjaria JB, Caruso M, Russo C, Polosa R: EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS One. 2014; 8. doi: 10.1371/journal.pone.0066317. This article is the first published randomized trial of an e-cigarette
49. Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet. 2013;382:1629–37. This article is the most widely cited randomized trial of an e-cigarette for smoking cessation.
50. Dockrell M, Morison R, Bauld L, McNeill A. E-cigarettes: prevalence and attitudes in Great Britain. Nicotine Tob Res. 2013;15:1737–44. doi:10.1093/ntr/ntt057.
51. Brown J, Beard E, Kotz D, Michie S, West R. Real-world effectiveness of e-cigarettes when used to aid smoking cessation: a cross-sectional population study. Addiction. 2014. doi:10.1111/add.12623. This article provides first-time population data from the UK, indicating that e-cigarettes have cessation potential.
52. West R. Smoking in England. http://www.smokinginengland.info/latest-statistics/. Accessed 25 July 2014. Fascinating new data from the UK on the possible role of e-cigarettes in reducing population smoking prevalence.
53. Zeller M, Hatsukami D. The strategic dialogue on tobacco harm reduction: a vision and blueprint for action in the US. Tob Control. 2009;18:324–32.
54. Foulds J, Veldheer S, Berg A. Electronic cigarettes (e-cigs): views of aficionados and clinical/public health perspectives. Int J Clin Pract. 2011;65:1037–42.
55. Kralikova E, Novak J, West O, Kmetova A, Hajek P. Do e-cigarettes have the potential to compete with conventional cigarettes? A survey of conventional cigarette smokers’ experiences with e-cigarettes. Chest. 2013;18:12–2842.
56. Lechner WV, Tackett AP, Grant DM, Tahirkheli NN, Driskill LM, Wagener TL. Effects of duration of electronic cigarette use. Nicotine Tob Res. 2014. doi:10.1093/ntr/ntu061.
57. US Department of Health Education and Welfare: Smoking and health: report of the Advisory Committee to the Surgeon General of the Public Health Service. In Public Health Service Publication Washington: US Department of Health, Education and Welfare, Public Health Service. 1964.
58. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ. 2004;328:1519.
59. Benowitz NL, Hansson A, Jacob P. Cardiovascular effects of nasal and transdermal nicotine and cigarette smoking. Hypertension. 2002;39:1107–12.
60. Kimmel SE, Berlin JA, Miles C, Jaskowiak J, Carson JL, Strom BL. Risk of acute first myocardial infarction and use of nicotine patches in a general population. J Am Coll Cardiol. 2001;37:1297–302.
61. Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996;335:1792–8.
62. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol. 1997;29:1422–31.
63. Cheng T. Chemical evaluation of electronic cigarettes. Tob Control. 2014;23:2013–051482. This article provides an account of findings from a systematic literature review of the chemical constituents of e-cigarettes.
64. Pellegrino RM, Tinghino B, Mangiaracina G, Marani A, Vitali M, Protano C, et al. Electronic cigarettes: an evaluation of exposure to chemicals and fine particulate matter (PM). Ann Ig. 2012;24:279–88.
65. Callahan-Lyon P. Electronic cigarettes: human health effects. Tob Control. 2014;23:ii36–40. This article provides an account of findings from a systematic literature review of the health effects of e-cigarettes.
66. Bjartveit K, Tverdal A. Health consequences of smoking 1–4 cigarettes per day. Tob Control. 2005;14:315–20.
67. Bullen C, Whittaker R, McRobbie H, Fagerstrom K. A clinical imperative: assisting patients who smoke to reduce their risk of cardiovascular disease. Prev Cardiol. 2007;10:5–9.